Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy

Journal of Crohn's and Colitis

Volumn 6, Issue 6, 2012, Pages 698-707

  Gilissen, Lennard P L ^a   Wong, Dennis R ^b   Engels, Leopold G J B ^b   Bierau, Jörgen ^c   Bakker, Jaap A ^c   Paulussen, Aimée D C ^c   Romberg Camps, Mariëlle J ^b   Stronkhorst, Arnold ^a   Bus, Paul ^d   Bos, Laurens P ^b   Hooymans, Piet M ^b   Stockbrügger, Reinhold W ^c   Neef, Cees ^c,e   Masclee, Ad A M ^c  

^a CATHARINA HOSPITAL   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LAURENTIUS HOSPITAL   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

6 Mercaptopurine; Azathioprine; Inflammatory bowel disease; Non compliance; Therapeutic drug monitoring; Thiopurines

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE; TIOGUANINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; ENTERITIS; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGED; AZATHIOPRINE; BIOMARKERS, PHARMACOLOGICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; GENETIC MARKERS; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MAINTENANCE CHEMOTHERAPY; MALE; MEDICATION ADHERENCE; METHYLTRANSFERASES; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THIOINOSINE; THIONUCLEOTIDES; YOUNG ADULT;

EID: 84862233680     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.12.003     Document Type: Article

References (45)

1. Derijks L.J.J., Wong D.R. Pharmacogenetics of thiopurines in inflammatory bowel disease. Curr Pharm Des 2010, 16(2):145-154.
2. Weinshilboum R.M., Sladek S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980, 32(5):651-662.
3. Krynetski E.Y., Evans W.E. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 2000, 61(3):136-146.
4. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002, 51(2):143-146.
5. Dubinsky M.C., Lamothe S., Yang H.Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705-713.
6. Derijks L.J.J., Gilissen L.P.L., Engels L.G.J.B., Bos L.P., Bus P.J., Lohman J.J.H.M., et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease; implications for therapy. Ther Drug Monit 2004, 26(3):311-318.
7. Al Hadithy A.F., de Boer N.K., Derijks L.J., Escher J.C., Mulder C.J., Brouwers J.R. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis 2005, 37:282-297.
8. Cuffari C., Theoret Y., Latour S., et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996, 39:401-406.
9. Dubinsky M.C., Huiying Y., Hassard P.V., et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002, 122:904-915.
10. Sandborn W.J. Rational dosing of azathioprine and 6-mercaptopurine. Gut 2001, 48:591-592.
11. Achkar J.P., Stevens T., Easley K., Brzezinski A., Seidner D., Lashner B. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004, 10(4):339-345.
12. Goldenberg B.A., Rawsthorne P., Bernstein C.N. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004, 99(9):1744-1748.
13. Hindorf U., Lyrenas E., Nilsson A., Schmiegelow K. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand J Gastroenterol 2004, 39(11):1105-1112.
14. Wright S., Sanders D.S., Lobo A.J., Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004, 53(8):1123-1128.
15. Cuffari C., Hunt S., Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001, 48(5):642-646.
16. Belaiche J., Desager J.P., Horsmans Y., Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001, 36(1):71-76.
17. Lowry P.W., Franklin C.L., Weaver A.L., Pike M.G., Mays D.C., Tremaine W.J., et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001, 49(5):665-670.
18. Gupta P., Gokhale R., Kirschner B.S. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001, 33(4):450-454.
19. Osterman M.T., Kundu R., Lichtenstein G.R., Lewis J.D. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006, 130:1047-1053.
20. De Boer N.K., Wong D.R., Jharap B., de Graaf P., Hooymans P.M., Mulder C.J., et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 2007, 102:1-7.
21. Roblin X., Serre-Debeauvais F., Phelip J.-M., Bessard G., Bonaz B. Drug interaction between infliximab and azathioprine in patients with Crohn's disease. Aliment Pharmacol Ther 2003, 18:917-925.
22. Lichtiger S., Present D.H., Kornbluth A., Gelernt I., Bauer J., Galler G., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330(26):1841-1845.
23. Lennard L., Singleton H.J. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992, 583(1):83-90.
24. Jacques-Aigrain E., Bessa E., Medard Y., Mircheva Y., Vilmer E. Thiopurine methyltransferase activity in a French population: HPLC assay conditions and effects of drugs and inhibitors. Br J Clin Pharmacol 1994, 38(1):1-8.
25. Gilissen L.P., Derijks L.J., Bos L.P., Bus P.J., Hooymans P.M., Engels L.G. Therapeutic drug monitoring in 15 patients with inflammatory bowel disease and established azathioprine therapy. Clin Drug Investig 2004, 24:479-486.
26. Kane S.V., Cohen R.D., Aikens J.E., Hanauer S.B. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001, 96(10):2929-2933.
27. Sewitch M.J., Abrahamowicz M., Barkun A., Bitton A., Wild G.E., Cohen A., et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003, 98(7):1535-1544.
28. Kane S.V., Huo D., Aikens J.E., Hanauer S.B. Medication nonadherence and the outcome of patients with quiescent ulcerative colitis. Am J Med 2003, 114(1):39-43.
29. Wong D.R., Derijks L.J.J., den Dulk M.O., Gemmeke E.H.K.M., Hooymans P.M. The role of xanthine oxidase in thiopurine metabolism: a case report. Ther Drug Monit 2007, 29:845-848.
30. Gilissen L.P., Derijks L.J., Verhoeven H.M., Bierau J., Hooymans P.M., Hommes D.W., et al. Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease. Dig Liver Dis 2007, 39(2):182-186.
31. Ansari A., Hassan C., Duley J., Marinaki A., Shobowale-Bakre E.M., Seed P., et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16(10):1743-1750.
32. Campbell S., Kingstone K., Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther 2002, 16(3):389-398.
33. Regueiro M., Mardini H. Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. J Clin Gastroenterol 2002, 35(3):240-244.
34. Kwan L.Y., Devlin S.M., Mirocha J.M., Papadakis K.A. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. Dig Liver Dis 2008, 40:425-432.
35. Pearson D.C., May G.R., Fick G.H., Sutherland L.R. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995, 123:132-142.
36. Kaskas B.A., Louis E., Hindorf U., Schaeffeler E., Deflandre J., Graepler F., et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003, 52(1):140-142.
37. Mayer L. When is too much enough?. Gastroenterology 2006, 130(4):1352-1354.
38. Reinshagen M., Schütz E., Armstrong V.W., Behrens C., Von Tirpitz C., Stallmach A., et al. 6-Thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007, 53:1306-1314.
39. González-Lama Y., Bermejo F., López-Sanromán A., García-Sánchez V., Esteve M., Cabriada J.L., et al. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther 2011, 34:544-554.
40. Jharap B., Seinen M.L., De Boer N.K.H., Van Ginkel J.R., Linskens R.K., Kneppelhout J.C., et al. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010, 16(9):1541-1549.
41. Hanai H., Iida T., Takeuchi K., Arai O., Watanabe F., Abe J., et al. Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide. Inflamm Bowel Dis 2010, 16(8):1376-1381.
42. Haines M.L., Ajlouni Y., Irving P.M., Sparrow M.P., Rose R., Gearry R.B., et al. Clinical usefulness of therapeutic drug monitoring in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011, 17(6):1301-1307.
43. Roblin X., Oussalah A., Chevaux J.-B., Sparrow M., Peyrin-Biroulet L. Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts. Inflamm Bowel Dis 2011, 17(12):2480-2487.
44. Van Asseldonk D.P., Sanderson J., de Boer N.K.H., Sparrow M.P., Lémann M., Ansari A., et al. Thiopurine Task Force Interest Group. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease-proceedings of the first Thiopurine Task Force meeting. Dig Liver Dis 2011, 43:270-276.
45. Van Asseldonk D.P., de Boer N.K.H., van Bodegraven A.A. Thiopurine metabolite measurement - not for everyone. Aliment Pharmacol Ther 2011, 34:1038-1039.